Pharmaceutical - Anti-virals, GlaxoSmithKline

Filter

Popular Filters

1 to 25 of 35 results

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

03-07-2014

USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

ViiV Healthcare links with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

12-06-2014

ViiV Healthcare today announced that they have entered into an agreement with Janssen R&D Ireland, a…

Anti-viralsEdurantGlaxoSmithKlineJanssenJohnson & JohnsonLicensingPharmaceuticalResearchTivicayViiV Healthcare

IQWIG finds added benefit in adult patients for VIIV Healthcare’s Tivicay

27-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTivicayViiV Healthcare

2014 “drugs to watch” as potential blockbusters

2014 “drugs to watch” as potential blockbusters

17-04-2014

The Thomson Reuters Intellectual Property & Science business has released its annual forecast of the…

AfrezzaAnoro ElliptaAnti-viralsCyramzaEli LillyGilead SciencesGlaxoSmithKlineidelalisibMannKindMarkets & MarketingOncologyPharmaceuticalRespiratory and PulmonarySovaldi

Brazil National Health System coverage of and access to HIV drugs

Brazil National Health System coverage of and access to HIV drugs

27-12-2013

Brazil’s National Health System (SUS) currently provides coverage for 22 drugs that are distributed…

AbbVieAnti-viralsAtriplaBrazilEvipleraGilead SciencesGlaxoSmithKlineHealthcareKaletra TabletsMarkets & MarketingPharmaceuticalSouth AmericaTriovirTruvadaViread

New agreement with GSK provides new medicines, saves millions for New Zealand

New agreement with GSK provides new medicines, saves millions for New Zealand

11-12-2013

A new agreement with the local subsidiary of UK pharma giant GlaxoSmithKline by New Zealand’s Pharmaceutical…

Anti-viralsAsia-PacificGlaxoSmithKlineHealthcareHematologyNew ZealandPharmaceuticalPricingRespiratory and PulmonarySeretideSerevent Diskus

ViiV Healthcare’s Tivicay approved in Canada for HIV

04-11-2013

ViiV Healthcare, the HIV/AIDS joint venture set up by UK pharma giant GlaxoSmithKline with US behemoth…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

AHF sues GSK for failing to provide discounts on HIV/AIDS drugs

11-09-2013

The USA-based AIDS Healthcare Foundation (AHF) said yesterday (September 10) that it has filed a law…

Anti-viralsGlaxoSmithKlineLegalNorth AmericaPharmaceuticalPricing

FDA approves new ViiV Healthcare HIV drug

13-08-2013

The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

US FDA approves shipment of quadrivalent flu vaccine to health care providers

06-08-2013

The US subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) says it has received Food and Drug Administration…

Anti-viralsFluarixGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

Regulatory updates for Tris Pharma's Karbinal; GSK's four-strain seasonal flu vaccine

03-04-2013

US drug delivery specialist Tris Pharma says that the US Food and Drug Administration has approved its…

Anti-viralsEuropeFluarixGlaxoSmithKlineInflusplit TetraKarbinalNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryTris Pharma

GlaxoSmithKline and Abbott to start production in Ukraine

19-03-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and the USA's Abbott (NYSE: ABT) are considering launching…

Anti-viralsAntibiotics and Infectious diseasesEuropeGlaxoSmithKlineIndarPharmaceuticalProductionVaccines

Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113

07-03-2013

UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

Clinical updates at ROI meeting on GSK's dolutegravir and Medivir's simeprevir

07-03-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drug major Shionogi (TYO: 4507) reported interim…

Anti-viralsdolutegravirGlaxoSmithKlineMedivirPharmaceuticalResearchShionogisimeprevir

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir

18-02-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

Japan's seasonal flu vaccines market analysis

16-01-2013

The Japanese influenza vaccine market is valued at around $702 million in 2012, according to a new report…

Anti-viralsAsia-PacificGlaxoSmithKlineMarkets & MarketingPharmaceuticalSanofiVaccines

Flu vaccine innovation needed to protect children, says GlobalData health care expert

13-01-2013

The last time the USA confronted a flu season this early, the virus claimed the lives of nearly 50,000…

Anti-viralsAstraZenecaFluarixFluMistGlaxoSmithKlinePharmaceuticalResearchVaccines

Sales of antiretroviral agents for HIV will decline slightly over next decade

18-12-2012

Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

ViiV Healthcare's dolutegravir shows promise in hard-to-treat HIV patients

16-11-2012

ViiV Healthcare, and HIV/AIDS company jointly owned by GlaxoSmithKline (LSE: GSK), Pfizer (NYSE: PFE)…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalResearchShionogiViiV Healthcare

Vertex links with Janssen and GlaxoSmithKline for combo trials with its VX-135 for hepatitis C

02-11-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) Janssen Pharmaceuticals unit has entered into a…

Anti-viralsBiotechnologyGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirVertexVX-135

Revised terms for ViiV Healthcare and Shionogi HIV partnership

30-10-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that Healthcare, its HIV/AIDS joint venture with Pfizer,…

Anti-viralsdolutegravirGlaxoSmithKlineMergers & AcquisitionsPfizerPharmaceuticalShionogiViiV Healthcare

Shionogi-Viiv Healthcare to start regulatory filing of dolutegravir by year-end

08-10-2012

Shionogi-ViiV Healthcare, a joint venture between Japan's Shionogi (TYO: 4507) and ViiV Healthcare, a…

Anti-viralsdolutegravirGlaxoSmithKlinePfizerPharmaceuticalRegulationResearchShionogiShionogi-ViiV HealthcareViiV Healthcare

1 to 25 of 35 results

Back to top